Atrial fibrillation is the most common heart rhythm disorder, affecting millions of people worldwide. Current treatment includes blood thinners to prevent stroke, medications to control heart rate or rhythm, and procedures like catheter ablation that destroy the tissue causing irregular beats.
What's actually going on in research
Trials are testing new ablation techniques including pulsed field ablation that avoids damaging nearby structures, longer-acting blood thinners, drugs that target specific ion channels in heart muscle, and device-based approaches to detect AFib earlier. Researchers are also studying ways to predict who will develop AFib and whether earlier treatment prevents progression.
Pulsed field ablation
This newer ablation method uses electrical pulses instead of heat or cold to destroy abnormal tissue. Early studies show it may work faster and cause less damage to the esophagus and nerves near the heart.
Factor XI inhibitors
These blood thinners block a different clotting protein than current drugs. Trials are testing whether they prevent stroke with less bleeding risk, particularly brain bleeding.
Early rhythm control
Studies suggest that treating AFib aggressively within the first year may prevent heart damage and improve long-term outcomes. Trials are testing whether this approach works across different patient groups.
What to know before you search
Eligibility typically depends on AFib type (paroxysmal, persistent, or permanent), symptoms, prior treatments including ablation, stroke risk factors, and other heart conditions.
What types of trials are currently open
- Ablation trials — Testing catheter procedures that destroy abnormal heart tissue, comparing different energy sources and techniques to see which works best with fewer complications.
- Blood thinner trials — Testing new anticoagulants or comparing dosing strategies to find the best balance between preventing stroke and avoiding bleeding.
- Rhythm drug trials — Testing medications that restore normal rhythm, often comparing them to rate control or ablation.
- Device trials — Testing implantable monitors or wearables that detect AFib episodes, often studying whether early detection leads to better treatment decisions.
- Lifestyle trials — Testing weight loss, exercise programs, or alcohol reduction to see if they reduce AFib burden or prevent progression.
Recently added Atrial Fibrillation trials
AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational Study
Stroke is a leading cause of death and adult disability. Stroke care is still limited by fragmented care pathways, non-standardised diagnostic work-up and follow-up, and local, non-interoperable data systems across the pre-hospital, in-hospital and post-hospital settings. UMBRELLA-P is a multicentre, prospective, observational study in 7 university hospitals in 6 European countries (Spain, Italy, Belgium, the Netherlands, Germany and Switzerland). Adults with clinically suspected acute stroke or transient ischemic attack (TIA) are managed according to standard of care. Routine clinical, imaging, laboratory, ECG and patient-reported data are collected, pseudonymised, stored on a dedicated server at each hospital and harmonised to the OMOP Common Data Model. The harmonised data form a federated real-world data platform (U-Platform). On this platform, artificial intelligence (AI) models are trained and validated through federated learning, so that no patient data leave the participating sites. The models aim to predict short- and long-term outcomes, reduce time to treatment, and support diagnosis, triage, discharge, follow-up and secondary prevention. Five clinical sub-studies address pre-hospital triage, fast track to reperfusion, emergent intracerebral hemorrhage (ICH) management, TIA/minor stroke, and cardiac evaluation with blood biomarkers. The study is observational. The outputs of the AI models are used for research only and will not influence clinical decisions. Participants are followed for up to 12 months.
Structured Treatment and Resource Efficiency Assessment With Lean Six Sigma Integration for Pulmonary Vein Isolation
The STREAMLINE-PVI trial is a prospective, single-center, randomized, open-label clinical trial comparing pulsed field ablation (PFA) with cryoballoon ablation (Cryo) for pulmonary vein isolation (PVI) in patients with atrial fibrillation (AF). A total of 94 patients undergoing first-time PVI will be randomized 1:1 to either PFA or Cryo within standardized Lean Six Sigma (LSS)-optimized procedural workflows. The primary objective is to evaluate whether PFA reduces total procedure duration by at least 20% compared with Cryo without compromising safety or efficacy. Secondary outcomes include post-procedural recovery, readiness for same-day discharge, atrial arrhythmia recurrence, AF burden, and procedural complications during a 12-month follow-up period.
Find Atrial Fibrillation trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.